Merops Switch to
Inhibitors

Peptidase

Family Clan SEARCHES BLAST
MEROPS SUBMISSIONS

Other
information

Literature for peptidase S01.212: plasma kallikrein

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

(Topics flags: A Assay, S Structure, T Target, P Specificity, K Knockout, E Expression, V Review, M Mutation, I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

    2024
  1. Kearney,K.J., Spronk,H.M.H., Emsley,J., Key,N.S. and Philippou,H.
    Plasma Kallikrein as a Forgotten Clotting Factor
    Semin Thromb Hemost50, 953-961. PubMed  Europe PubMed DOI  V
  2. Longhurst,H.J., Lindsay,K., Petersen,R.S., Fijen,L.M., Gurugama,P., Maag,D., Butler,J.S., Shah,M.Y., Golden,A., Xu,Y., Boiselle,C., Vogel,J.D., Abdelhady,A.M., Maitland,M.L., McKee,M.D., Seitzer,J., Han,B.W., Soukamneuth,S., Leonard,J., Sepp-Lorenzino,L., Clark,E.D., Lebwohl,D. and Cohn,D.M.
    CRISPR-Cas9 In Vivo Gene Editing of KLKB1 for Hereditary Angioedema
    N Engl J Med390, 432-441. PubMed  Europe PubMed DOI
  3. Riedl,M.A., Bordone,L., Revenko,A., Newman,K.B. and Cohn,D.M.
    Clinical Progress in Hepatic Targeting for Novel Prophylactic Therapies in Hereditary Angioedema
    J Allergy Clin Immunol Pract12, 911-918. PubMed  Europe PubMed DOI  K
    4. 2023
  4. Bedian,V., Biris,N., Omer,C., Chung,J.K., Fuller,J., Dagher,R., Chandran,S., Harwin,P., Kiselak,T., Violin,J., Nichols,A. and Bista,P.
    STAR-0215 is a Novel, Long-Acting Monoclonal Antibody Inhibitor of Plasma Kallikrein for the Potential Treatment of Hereditary Angioedema
    J Pharmacol Exp Ther387, 214-225. PubMed  Europe PubMed DOI
  5. Li,C., Barroeta,A.B., Wong,S.S., Kim,H.J., Pathak,M., Dreveny,I., Meijers,J.C.M. and Emsley,J.
    Structures of factor XI and prekallikrein bound to domain 6 of high-molecular weight kininogen reveal alternate domain 6 conformations and exosites
    J Thromb Haemost21, 2378-2389. PubMed  Europe PubMed DOI
  6. Motta,G., Juliano,L. and Chagas,J.R.
    Human plasma kallikrein: roles in coagulation, fibrinolysis, inflammation pathways, and beyond
    Front Physiol14, 1188816-1188816. PubMed  Europe PubMed DOI  V
    7. 2022
  7. Alfaro,E., Diaz-Garcia,E., Garcia-Tovar,S., Zamarron,E., Mangas,A., Galera,R., Nanwani-Nanwani,K., Perez-de-Diego,R., Lopez-Collazo,E., Garcia-Rio,F. and Cubillos-Zapata,C.
    Impaired Kallikrein-Kinin System in COVID-19 Patients' Severity
    Front Immunol13, 909342-909342. PubMed  Europe PubMed DOI
  8. Davie,R.L., Edwards,H.J., Evans,D.M., Hodgson,S.T., Stocks,M.J., Smith,A.J., Rushbrooke,L.J., Pethen,S.J., Roe,M.B., Clark,D.E., McEwan,P.A. and Hampton,S.L.
    Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema
    J Med Chem65, 13629-13644. PubMed  Europe PubMed DOI  I
  9. Sohaei,D., Hollenberg,M., Janket,S.J., Diamandis,E.P., Poda,G. and Prassas,I.
    The therapeutic relevance of the Kallikrein-Kinin axis in SARS-cov-2-induced vascular pathology
    Crit Rev Clin Lab Sci1-16. PubMed  Europe PubMed DOI  V
  10. Wang,J.K., Li,Y., Zhao,X.L., Liu,Y.B., Tan,J., Xing,Y.Y., Adi,D., Wang,Y.T., Fu,Z.Y., Ma,Y.T., Liu,S.M., Liu,Y., Wang,Y., Shi,X.J., Lu,X.Y., Song,B.L. and Luo,J.
    Ablation of Plasma Prekallikrein Decreases Low-Density Lipoprotein Cholesterol by Stabilizing Low-Density Lipoprotein Receptor and Protects Against Atherosclerosis
    Circulation145, 675-687. PubMed  Europe PubMed DOI
    11. 2021
  11. Giangreco,N.P., Lebreton,G., Restaino,S., Jane Farr,M., Zorn,E., Colombo,P.C., Patel,J., LeVine,R., Truby,L., Soni,R.K., Leprince,P., Kobashigawa,J., Tatonetti,N.P. and Fine,B.M.
    Plasma kallikrein predicts primary graft dysfunction after heart transplant
    J Heart Lung Transplant PubMed  Europe PubMed DOI
  12. Kearney,K.J., Butler,J., Posada,O.M., Wilson,C., Heal,S., Ali,M., Hardy,L., Ahnstrom,J., Gailani,D., Foster,R., Hethershaw,E., Longstaff,C. and Philippou,H.
    Kallikrein directly interacts with and activates Factor IX, resulting in thrombin generation and fibrin formation independent of Factor XI
    Proc Natl Acad Sci U S A118, PubMed  Europe PubMed DOI
  13. Wan,J., Vadaq,N., Konings,J., Jaeger,M., Kumar,V., de Laat,B., Joosten,L., Netea,M.G., van der Ven,A.J., DE Groot,P.G., de Mast,Q. and Roest,M.
    Kallikrein augments the anticoagulant function of the protein C system in thrombin generation
    J Thromb Haemost PubMed  Europe PubMed DOI
    14. 2020
  14. Chatterjee,P., Gheblawi,M., Wang,K., Vu,J., Kondaiah,P. and Oudit,G.Y.
    Interaction between the apelinergic system and ACE2 in the cardiovascular system: therapeutic implications
    Clin Sci (Lond)134, 2319-2336. PubMed  Europe PubMed DOI  V
  15. Fang,C. and Schmaier,A.H.
    Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems
    Pharmacol Res160, 105096-105096. PubMed  Europe PubMed DOI  V
  16. Ivanov,I., Verhamme,I.M., Sun,M.F., Mohammed,B., Cheng,Q., Matafonov,A., Dickeson,S.K., Joseph,K., Kaplan,A.P. and Gailani,D.
    Protease activity in single-chain prekallikrein
    Blood135, 558-567. PubMed  Europe PubMed DOI
  17. Meini,S., Zanichelli,A., Sbrojavacca,R., Iuri,F., Roberts,A.T., Suffritti,C. and Tascini,C.
    Understanding the Pathophysiology of COVID-19: Could the Contact System Be the Key?
    Front Immunol11, 2014-2014. PubMed  Europe PubMed DOI
  18. Ponczek,M.B., Shamanaev,A., LaPlace,A., Dickeson,S.K., Srivastava,P., Sun,M.F., Gruber,A., Kastrup,C., Emsley,J. and Gailani,D.
    The evolution of factor XI and the kallikrein-kinin system
    Blood Adv4, 6135-6147. PubMed  Europe PubMed DOI
  19. Xie,Z., Li,Z., Shao,Y. and Liao,C.
    Discovery and development of plasma kallikrein inhibitors for multiple diseases
    Eur J Med Chem190, 112137-112137. PubMed  Europe PubMed DOI  I
    20. 2019
  20. Fischer,C., Lamer,T., Wang,W., McKinnie,S.M.K., Iturrioz,X., Llorens-Cortes,C., Oudit,G.Y. and Vederas,J.C.
    Plasma kallikrein cleaves and inactivates apelin-17: palmitoyl- and PEG-extended apelin-17 analogs as metabolically stable blood pressure-lowering agents
    Eur J Med Chem166, 119-124. PubMed  Europe PubMed DOI
  21. Hwang,G., Johri,A., Ng,S. and Craig,T.
    A review of kallikrein inhibitor lanadelumab in hereditary angioedema
    Immunotherapy11, 937-944. PubMed  Europe PubMed DOI
  22. Hwang,J.R., Hwang,G., Johri,A. and Craig,T.
    Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema
    Immunotherapy11, 1439-1444. PubMed  Europe PubMed DOI  I
  23. Li,C., Voos,K.M., Pathak,M., Hall,G., McCrae,K.R., Dreveny,I., Li,R. and Emsley,J.
    Plasma Kallikrein Structure Reveals Apple Domain Disc Rotated Conformation Compared to Factor XI
    J Thromb Haemost17, 759-770. PubMed  Europe PubMed DOI  S
  24. Partridge,J.R., Choy,R.M., Silva-Garcia,A., Yu,C., Li,Z., Sham,H. and Metcalf,B.
    Structures of full-length plasma kallikrein bound to highly specific inhibitors describe a new mode of targeted inhibition
    J Struct Biol206, 170-182. PubMed  Europe PubMed DOI  S  I
  25. Salu,B.R., Pando,S.C., Brito,M.V., Medina,A.F., Odei-Addo,F., Frost,C., Naude,R., Sampaio,M.U., Emsley,J., Maffei,F.H.A. and Oliva,M.L.V.
    Improving the understanding of plasma kallikrein contribution to arterial thrombus formation using two plant protease inhibitors
    Platelets30, 305-313. PubMed  Europe PubMed DOI
  26. Sun,J.K., Maturi,R.K., Boyer,D.S., Wells,J.A., Gonzalez,V.H., Tansley,R., Hernandez,H., Maetzel,A., Feener,E.P. and Aiello,L.P.
    One-time intravitreal injection of KVD001, a plasma kallikrein inhibitor, in patients with central-involved diabetic macular edema and reduced vision: an open-label phase 1B study
    Ophthalmol Retina3, 1107-1109. PubMed  Europe PubMed DOI  I
  27. Wedi,B.
    Lanadelumab to treat hereditary angioedema
    Drugs Today (Barc)55, 439-448. PubMed  Europe PubMed DOI
    28. 2018
  28. Aygoren-Pursun,E., Bygum,A., Grivcheva-Panovska,V., Magerl,M., Graff,J., Steiner,U.C., Fain,O., Huissoon,A., Kinaciyan,T., Farkas,H., Lleonart,R., Longhurst,H.J., Rae,W., Triggiani,M., Aberer,W., Cancian,M., Zanichelli,A., Smith,W.B., Baeza,M.L., Du-Thanh,A., Gompels,M., Gonzalez-Quevedo,T., Greve,J., Guilarte,M., Katelaris,C., Dobo,S., Cornpropst,M., Clemons,D., Fang,L., Collis,P., Sheridan,W., Maurer,M. and Cicardi,M.
    Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema
    N Engl J Med379, 352-362. PubMed  Europe PubMed DOI  I
  29. Irmscher,S., Doring,N., Halder,L.D., Jo,E.A.H., Kopka,I., Dunker,C., Jacobsen,I.D., Luo,S., Slevogt,H., Lorkowski,S., Beyersdorf,N., Zipfel,P.F. and Skerka,C.
    Kallikrein cleaves C3 and activates complement
    J Innate Immun10, 94-105. PubMed  Europe PubMed DOI
  30. Riedl,M.A., Aygoren-Pursun,E., Baker,J., Farkas,H., Anderson,J., Bernstein,J.A., Bouillet,L., Busse,P., Manning,M., Magerl,M., Gompels,M., Huissoon,A.P., Longhurst,H., Lumry,W., Ritchie,B., Shapiro,R., Soteres,D., Banerji,A., Cancian,M., Johnston,D.T., Craig,T.J., Launay,D., Li,H.H., Liebhaber,M., Nickel,T., Offenberger,J., Rae,W., Schrijvers,R., Triggiani,M., Wedner,H.J., Dobo,S., Cornpropst,M., Clemons,D., Fang,L., Collis,P., Sheridan,W.P. and Maurer,M.
    Evaluation of avoralstat, an oral kallikrein inhibitor, in a phase 3 hereditary angioedema prophylaxis trial: the OPUS-2 study
    Allergy73, 1871-1880. PubMed  Europe PubMed DOI  I
  31. Teufel,D.P., Bennett,G., Harrison,H., van Rietschoten,K., Pavan,S., Stace,C., Le Floch,F., Van Bergen,T., Vermassen,E., Barbeaux,P., Hu,T.T., Feyen,J.H.M. and Vanhove,M.
    Stable and long-lasting, novel bicyclic peptide plasma kallikrein inhibitors for the treatment of diabetic macular edema
    J Med Chem61, 2823-2836. PubMed  Europe PubMed DOI  I
  32. Xu,M., Chen,Y., Xu,P., Andreasen,P.A., Jiang,L., Li,J. and Huang,M.
    Crystal structure of plasma kallikrein reveals the unusual flexibility of the S1 pocket triggered by Glu217
    FEBS Lett592, 2658-2667. PubMed  Europe PubMed DOI  S
    33. 2017
  33. Abdel-Magid,A.F.
    Plasma kallikrein inhibitors for the treatment of retinal vascular permeability associated with diabetic retinopathy and diabetic macular edema
    ACS Med Chem Lett8, 776-777. PubMed  Europe PubMed DOI  I
  34. Ivanov,I., Matafonov,A., Sun,M.F., Cheng,Q., Dickeson,S.K., Verhamme,I.M., Emsley,J. and Gailani,D.
    Proteolytic properties of single-chain factor XII: a mechanism for triggering contact activation
    Blood129, 1527-1537. PubMed  Europe PubMed DOI
  35. Li,Z., Partridge,J., Silva-Garcia,A., Rademacher,P., Betz,A., Xu,Q., Sham,H., Hu,Y., Shan,Y., Liu,B., Zhang,Y., Shi,H., Xu,Q., Ma,X. and Zhang,L.
    Structure-guided design of novel, potent, and selective macrocyclic plasma kallikrein inhibitors
    ACS Med Chem Lett8, 185-190. PubMed  Europe PubMed DOI  I
  36. Simao,F., Ustunkaya,T., Clermont,A.C. and Feener,E.P.
    Plasma kallikrein mediates brain hemorrhage and edema caused by tissue plasminogen activator therapy in mice after stroke
    Blood129, 2280-2290. PubMed  Europe PubMed DOI
  37. Steen Burrell,K.A., Layzer,J. and Sullenger,B.A.
    A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release
    J Thromb Haemost15, 1807-1817. PubMed  Europe PubMed DOI  I
  38. Xu,M.-M., Xu,P., Zhou,X.-L., Andreasen,P., Jiang,L.-G. and Huang,M.-D.
    Crystal structures of the serine protease domain of murine plasma kallikrein
    Jiegou Huaxue36, 242-249. DOI  S
    39. 2016
  39. Clermont,A., Murugesan,N., Zhou,Q., Kita,T., Robson,P.A., Rushbrooke,L.J., Evans,D.M., Aiello,L.P. and Feener,E.P.
    Plasma kallikrein mediates vascular endothelial growth factor-induced retinal dysfunction and thickening
    Invest Ophthalmol Vis Sci57, 2390-2399. PubMed  Europe PubMed DOI  I
  40. Cornpropst,M., Collis,P., Collier,J., Babu,Y.S., Wilson,R., Zhang,J., Fang,L., Zong,J. and Sheridan,W.P.
    Safety, pharmacokinetics, and pharmacodynamics of avoralstat, an oral plasma kallikrein inhibitor: phase 1 study
    Allergy71, 1676-1683. PubMed  Europe PubMed DOI  I
  41. Gittleman,H.R., Merkulova,A., Alhalabi,O., Stavrou,E.X., Veigl,M.L., Barnholtz-Sloan,J.S. and Schmaier,A.H.
    A cross-sectional study of KLKB1 and PRCP polymorphisms in patient samples with cardiovascular disease
    Front Med (Lausanne)3, 17-17. PubMed  Europe PubMed DOI  M
  42. Gras,J.
    Anti-KLKB1 (plasma kallikrein) MAb treatment of hereditary angioedema
    Drugs Future41, 281-284. DOI
  43. Kokoye,Y., Ivanov,I., Cheng,Q., Matafonov,A., Dickeson,S.K., Mason,S., Sexton,D.J., Renne,T., McCrae,K., Feener,E.P. and Gailani,D.
    A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation
    Thromb Res140, 118-124. PubMed  Europe PubMed DOI  M
  44. Kolte,D. and Shariat-Madar,Z.
    Plasma kallikrein inhibitors in cardiovascular disease: an innovative therapeutic approach
    Cardiol Rev24, 99-109. PubMed  Europe PubMed DOI  I
    45. 2015
  45. Adamopoulos,P.G., Kontos,C.K., Papageorgiou,S.G., Pappa,V. and Scorilas,A.
    KLKB1 mRNA overexpression: a novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia
    Clin Biochem48, 849-854. PubMed  Europe PubMed DOI
  46. Renne,T.
    The vascular side of plasma kallikrein
    Blood125, 589-590. PubMed  Europe PubMed DOI  K
  47. Xu,P., Xu,M., Jiang,L., Yang,Q., Luo,Z., Dauter,Z., Huang,M. and Andreasen,P.A.
    Design of specific serine protease inhibitors based on a versatile peptide scaffold: conversion of a urokinase inhibitor to a plasma kallikrein inhibitor
    J Med Chem58, 8868-8876. PubMed  Europe PubMed DOI  I
    48. 2014
  48. Kenniston,J.A., Faucette,R.R., Martik,D., Comeau,S.R., Lindberg,A.P., Kopacz,K.J., Conley,G.P., Chen,J., Viswanathan,M., Kastrapeli,N., Cosic,J., Mason,S., DiLeo,M., Abendroth,J., Kuzmic,P., Ladner,R.C., Edwards,T.E., Tenhoor,C., Adelman,B.A., Nixon,A.E. and Sexton,D.J.
    Inhibition of plasma kallikrein by a highly specific active site blocking antibody
    J Biol Chem289, 23596-23608. PubMed  Europe PubMed DOI
  49. Keum,J.S., Jaffa,M.A., Luttrell,L.M. and Jaffa,A.A.
    Novel mechanism of plasma prekallikrein (PK) activation by vascular smooth muscle cells: evidence of the presence of PK activator
    J Biol Regul Homeost Agents28, 587-603. PubMed  Europe PubMed
  50. Schmaier,A.H.
    Physiologic activities of the contact activation system
    Thromb Res133 Suppl 1, S41-S44. PubMed  Europe PubMed DOI  K
  51. Wang,J., Matafonov,A., Madkhali,H., Mahdi,F., Watson,D., Schmaier,A.H., Gailani,D. and Shariat-Madar,Z.
    Prolylcarboxypeptidase independently activates plasma prekallikrein (Fletcher factor)
    Curr Mol Med14, 1173-1185. PubMed  Europe PubMed
    52. 2013
  52. Bjorkqvist,J., Jamsa,A. and Renne,T.
    Plasma kallikrein: the bradykinin-producing enzyme
    Thromb Haemost110, 399-407. PubMed  Europe PubMed DOI  V
  53. Koumandou,V.L. and Scorilas,A.
    Evolution of the plasma and tissue kallikreins, and their alternative splicing isoforms
    PLoS ONE8, e68074-e68074. PubMed  Europe PubMed DOI
  54. Wong,M.K. and Takei,Y.
    Lack of plasma kallikrein-kinin system cascade in teleosts
    PLoS ONE8, e81057-e81057. PubMed  Europe PubMed DOI
    55. 2012
  55. Baeriswyl,V., Rapley,H., Pollaro,L., Stace,C., Teufel,D., Walker,E., Chen,S., Winter,G., Tite,J. and Heinis,C.
    Bicyclic peptides with optimized ring size inhibit human plasma kallikrein and its orthologues while sparing paralogous proteases
    ChemMedChem7, 1173-1176. PubMed  Europe PubMed DOI  I
  56. Bird,J.E., Smith,P.L., Wang,X., Schumacher,W.A., Barbera,F., Revelli,J.P. and Seiffert,D.
    Effects of plasma kallikrein deficiency on haemostasis and thrombosis in mice: murine ortholog of the Fletcher trait
    Thromb Haemost107, 1141-1150. PubMed  Europe PubMed DOI  K
  57. Renne,T. and Gruber,A.
    Plasma kallikrein: novel functions for an old protease
    Thromb Haemost107, 1012-1013. PubMed  Europe PubMed DOI
  58. Schmaier,A.H.
    Prekallikrein and plasma kallikrein
    [ISSN:978-0-12-407742-3]3, 2885-2892. DOI
    59. 2011
  59. Kolte,D., Bryant,J., Holsworth,D., Wang,J., Akbari,P., Gibson,G. and Shariat-Madar,Z.
    Biochemical characterization of a novel high-affinity and specific plasma kallikrein inhibitor
    Br J Pharmacol162, 1639-1649. PubMed  Europe PubMed DOI  I
  60. Revenko,A.S., Gao,D., Crosby,J.R., Bhattacharjee,G., Zhao,C., May,C., Gailani,D., Monia,B.P. and Macleod,A.R.
    Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding
    Blood118, 5302-5311. PubMed  Europe PubMed DOI  K
    61. 2010
  61. Stoop,A.A., Joshi,R.V., Eggers,C.T. and Craik,C.S.
    Analysis of an engineered plasma kallikrein inhibitor and its effect on contact activation
    Biol Chem391, 425-433. PubMed  Europe PubMed DOI
    62. 2009
  62. Abid,K., Rochat,B., Lassahn,P.G., Stocklin,R., Michalet,S., Brakch,N., Aubert,J.F., Vatansever,B., Tella,P., De Meester,I. and Grouzmann,E.
    Kinetic study of neuropeptide Y (NPY) proteolysis in blood and identification of NPY3-35: a new peptide generated by plasma kallikrein
    J Biol Chem284, 24715-24724. PubMed  Europe PubMed DOI  P
  63. Huang,W.Y., Wan,X. and Zhang,S.
    A novel chromogenic peptide for prekallikrein/kallikrein determination
    Clin Lab55, 106-113. PubMed  Europe PubMed  A
    64. 2008
  64. Lima,A.R., Alves,F.M., Angelo,P.F., Andrade,D., Blaber,S.I., Blaber,M., Juliano,L. and Juliano,M.A.
    S(1)' and S(2)' subsite specificities of human plasma kallikrein and tissue kallikrein 1 for the hydrolysis of peptides derived from the bradykinin domain of human kininogen
    Biol Chem389, 1487-1494. PubMed  Europe PubMed DOI  P
  65. Saito,A.
    Plasma kallikrein is activated on dermatan sulfate and cleaves factor H
    Biochem Biophys Res Commun370, 646-650. PubMed  Europe PubMed DOI
  66. Schmaier,A.H.
    Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system
    Int Immunopharmacol8, 161-165. PubMed  Europe PubMed DOI  V
  67. Stief,T.W.
    Kallikrein activates prothrombin
    Clin Appl Thromb Hemost14, 97-98. PubMed  Europe PubMed DOI
    68. 2007
  68. Colman,R.
    Kallikrein-kinin system
    9780521853767, 444-450. DOI  V
  69. Hooley,E., McEwan,P.A. and Emsley,J.
    Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation
    J Thromb Haemost5, 2461-2466. PubMed  Europe PubMed DOI
  70. Sainz,I.M., Pixley,R.A. and Colman,R.W.
    Fifty years of research on the plasma kallikrein-kinin system: from protein structure and function to cell biology and in-vivo pathophysiology
    Thromb Haemost98, 77-83. PubMed  Europe PubMed DOI  V
  71. Schmaier,A.H. and McCrae,K.R.
    The plasma kallikrein-kinin system: its evolution from contact activation
    J Thromb Haemost5, 2323-2329. PubMed  Europe PubMed DOI  V
  72. Schneider,L., Lumry,W., Vegh,A., Williams,A.H. and Schmalbach,T.
    Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor
    J Allergy Clin Immunol120, 416-422. PubMed  Europe PubMed DOI
    73. 2006
  73. [YEAR:4-11-2006]Biyashev,D., Tan,F., Chen,Z., Zhang,K., Deddish,P.A., Erdos,E.G. and Hecquet,C.
    Kallikrein activates bradykinin B2 receptors in absence of kininogen
    Am J Physiol Heart Circ Physiol290, H1244-H1250. PubMed  Europe PubMed DOI
  74. Levy,J.H. and O'Donnell,P.S.
    The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema
    Expert Opin Investig Drugs15, 1077-1090. PubMed  Europe PubMed DOI  T
  75. [YEAR:16-5-2006]Storini,C., Bergamaschini,L., Gesuete,R., Rossi,E., Maiocchi,D. and De Simoni,M.G.
    Selective inhibition of plasma kallikrein protects brain from reperfusion injury
    J Pharmacol Exp Ther318, 849-854. PubMed  Europe PubMed DOI
  76. [YEAR:11-1-2006]Young,W.B., Rai,R., Shrader,W.D., Burgess-Henry,J., Hu,H., Elrod,K.C., Sprengeler,P.A., Katz,B.A., Sukbuntherng,J. and Mordenti,J.
    Small molecule inhibitors of plasma kallikrein
    Bioorg Med Chem Lett16, 2034-2036. PubMed  Europe PubMed DOI  I
  77. Zhang,J., Krishnan,R., Arnold,C.S., Mattsson,E., Kilpatrick,J.M., Bantia,S., Dehghani,A., Boudreaux,B., Gupta,S.N., Kotian,P.L., Chand,P. and Babu,Y.S.
    Discovery of highly potent small molecule kallikrein inhibitors
    Med Chem2, 545-553. PubMed  Europe PubMed  I
    78. 2005
  78. Moreau,M.E., Garbacki,N., Molinaro,G., Brown,N.J., Marceau,F. and Adam,A.
    The kallikrein-kinin system: current and future pharmacological targets
    J Pharmacol Sci99, 6-38. PubMed  Europe PubMed DOI  V
  79. Neth,P., Arnhold,M., Sidarovich,V., Bhoola,K.D. and Fink,E.
    Expression of the plasma prekallikrein gene: utilization of multiple transcription start sites and alternative promoter regions
    Biol Chem386, 101-109. PubMed  Europe PubMed DOI
  80. Shariat-Madar,Z., Rahimy,E., Mahdi,F. and Schmaier,A.H.
    Overexpression of prolylcarboxypeptidase enhances plasma prekallikrein activation on Chinese hamster ovary cells
    Am J Physiol Heart Circ Physiol289, H2697-H2703. PubMed  Europe PubMed DOI
  81. [YEAR:30-9-2005]Tang,J., Yu,C.L., Williams,S.R., Springman,E., Jeffery,D., Sprengeler,P.A., Estevez,A., Sampang,J., Shrader,W., Spencer,J., Young,W., McGrath,M. and Katz,B.A.
    Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein
    J Biol Chem280, 41077-41089. PubMed  Europe PubMed DOI  E  S
    82. 2004
  82. Colman,R.W.
    Plasma prekallikrein and kallikrein
    [ISSN:0-12-079610-4]2, 1644-1651.  V
  83. [YEAR:2-3-2004]Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H.
    Recombinant prolylcarboxypeptidase activates plasma prekallikrein
    Blood103, 4554-4561. PubMed  Europe PubMed DOI  I
  84. Tanaka,K.A., Szlam,F., Katori,N., Vega,J.D. and Levy,J.H.
    Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro
    Thromb Res113, 333-339. PubMed  Europe PubMed DOI
  85. Wynne Jones,D., Russell,G., Allford,S.L., Burdon,K., Hawkins,G.A., Bowden,D.W., Minaee,S. and Mumford,A.D.
    Severe prekallikrein deficiency associated with homozygosity for an Arg94Stop nonsense mutation
    Br J Haematol127, 220-223. PubMed  Europe PubMed DOI
    86. 2003
  86. Jaffa,A.A., Durazo-Arvizu,R., Zheng,D., Lackland,D.T., Srikanth,S., Garvey,W.T. and Schmaier,A.H.
    Plasma prekallikrein: a risk marker for hypertension and nephropathy in type 1 diabetes
    Diabetes52, 1215-1221. PubMed  Europe PubMed DOI
  87. Lombardi,A.M., Sartori,M.T., Cabrio,L., Fadin,M., Zanon,E. and Girolami,A.
    Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr)
    Thromb Haemost90, 1040-1045. PubMed  Europe PubMed DOI  M
  88. Nunes,V.A., Gozzo,A.J., Sampaio,M.U., Juliano,M.A., Sampaio,C.A. and Araujo,M.S.
    Mapping of human plasma kallikrein active site by design of peptides based on modifications of a Kazal-type inhibitor reactive site
    J Protein Chem22, 533-541. PubMed  Europe PubMed DOI
  89. Stoop,A.A. and Craik,C.S.
    Engineering of a macromolecular scaffold to develop specific protease inhibitors
    Nat Biotechnol21, 1063-1068. PubMed  Europe PubMed DOI
    90. 2002
  90. [YEAR:22-1-2002]Joseph,K., Tholanikunnel,B.G. and Kaplan,A.P.
    Heat shock protein 90 catalyzes activation of the prekallikrein-kininogen complex in the absence of factor XII
    Proc Natl Acad Sci U S A99, 896-900. PubMed  Europe PubMed DOI
  91. [YEAR:6-12-2002]Peek,M., Moran,P., Mendoza,N., Wickramasinghe,D. and Kirchhofer,D.
    Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa
    J Biol Chem277, 47804-47809. PubMed  Europe PubMed DOI
  92. Renne,T., Sugiyama,A., Gailani,D., Jahnen-Dechent,W., Walter,U. and Muller-Esterl,W.
    Fine mapping of the H-kininogen binding site in plasma prekallikrein apple domain 2
    Int Immunopharmacol2, 1867-1873. PubMed  Europe PubMed DOI
  93. Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H.
    Assembly and activation of the plasma kallikrein/kinin system: a new interpretation
    Int Immunopharmacol2, 1841-1849. PubMed  Europe PubMed DOI
  94. [YEAR:17-5-2002]Shariat-Madar,Z., Mahdi,F. and Schmaier,A.H.
    Identification and characterization of prolylcarboxypeptidase as an endothelial cell prekallikrein activator
    J Biol Chem277, 17962-17969. PubMed  Europe PubMed DOI
    95. 2001
  95. [YEAR:1-6-2001]Melo,R.L., Alves,L.C., Del Nery,E., Juliano,L. and Juliano,M.A.
    Synthesis and hydrolysis by cysteine and serine proteases of short internally quenched fluorogenic peptides
    Anal Biochem293, 71-77. PubMed  Europe PubMed DOI
  96. [YEAR:1-5-2001]Melo,R.L., Barbosa Pozzo,R.C., Pimenta,D.C., Perissutti,E., Caliendo,G., Santagada,V., Juliano,L. and Juliano,M.A.
    Human tissue kallikrein S1 subsite recognition of non-natural basic amino acids
    Biochemistry40, 5226-5232. PubMed  Europe PubMed
  97. Neth,P., Arnhold,M., Nitschko,H. and Fink,E.
    The mRNAs of prekallikrein, factors XI and XII, and kininogen, components of the contact phase cascade are differentially expressed in multiple non-hepatic human tissues
    Thromb Haemost85, 1043-1047. PubMed  Europe PubMed
  98. Tada,M., Tsuda,Y., Wanaka,K., Hijikata-Okunomiya,A., Horie,N., Okamoto,U., Okamoto,S. and Okada,Y.
    Isolation of plasma kallikrein by high efficiency affinity chromatography and its characterization
    Biol Pharm Bull24, 520-524. PubMed  Europe PubMed DOI  I
    99. 2000
  99. Okada,Y., Tsuda,Y., Tada,M., Wanaka,K., Okamoto,U., Hijikata-Okunomiya,A. and Okamoto,S.
    Development of potent and selective plasmin and plasma kallikrein inhibitors and studies on the structure-activity relationship
    Chem Pharm Bull (Tokyo)48, 1964-1972. PubMed  Europe PubMed  I
  100. [YEAR:15-10-2000]Yu,H., Anderson,P.J., Freedman,B.I., Rich,S.S. and Bowden,D.W.
    Genomic structure of the human plasma prekallikrein gene, identification of allelic variants, and analysis in end-stage renal disease
    Genomics69, 225-234. PubMed  Europe PubMed DOI  M
    101. 1999
  101. Fukumizu,A., Tsuda,Y., Wanaka,K., Tada,M., Okamoto,S., Hijikata-Okunomiya,A. and Okada,Y.
    Amino acids and peptides. LIII. Synthesis and biological activities of some pseudo-peptide analogs of PKSI-527, a plasma kallikrein selective inhibitor: The importance of the peptide backbone
    Chem Pharm Bull (Tokyo)47, 1141-1144. PubMed  Europe PubMed  I
  102. Okada,Y., Tsuda,Y., Tada,M., Wanaka,K., Hijikata-Okunomiya,A., Okamoto,U. and Okamoto,S.
    Development of plasma kallikrein selective inhibitors
    Biopolymers51, 41-50. PubMed  Europe PubMed DOI  I
  103. [YEAR:3-9-1999]Renne,T., Dedio,J., Meijers,J.C., Chung,D. and Muller-Esterl,W.
    Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2
    J Biol Chem274, 25777-25784. PubMed  Europe PubMed DOI
  104. Shibuya,Y., Semba,U., Nishino,N., Khan,M.M., Tanase,S., Okabe,H. and Yamamoto,T.
    Primary structure of guinea pig plasma prekallikrein
    Immunopharmacology45, 127-134. PubMed  Europe PubMed DOI
    105. 1998
  105. [YEAR:1-1-1998]Kohyama,K., Ohnishi,J., Murata,M. and Takahashi,T.
    Presence of follipsin complexed with alpha2-macroglobulin in porcine ovarian follicular fluid
    J Exp Zool280, 57-64. PubMed  Europe PubMed DOI
  106. [YEAR:1-12-1998]Presnell,S.R., Patil,G.S., Mura,C., Jude,K.M., Conley,J.M., Bertrand,J.A., Kam,C.M., Powers,J.C. and Williams,L.D.
    Oxyanion-mediated inhibition of serine proteases
    Biochemistry37, 17068-17081. PubMed  Europe PubMed DOI  S  I
  107. Rojkjaer,R., Hasan,A.A., Motta,G., Schousboe,I. and Schmaier,A.H.
    Factor XII does not initiate prekallikrein activation on endothelial cells
    Thromb Haemost80, 74-81. PubMed  Europe PubMed
  108. Stadnicki,A., Sartor,R.B., Janardham,R., Majluf-Cruz,A., Kettner,C.A., Adam,A.A. and Colman,R.W.
    Specific inhibition of plasma kallikrein modulates chronic granulomatous intestinal and systemic inflammation in genetically susceptible rats
    FASEB J12, 325-333. PubMed  Europe PubMed
  109. Tada,M., Wanaka,K., Okamoto,S., Okamoto,U., Nakaya,Y., Horie,N., Hijikata-Okunomiya,A., Tsuda,Y. and Okada,Y.
    Purification method for human plasma kallikrein by a new affinity chromatography
    Biol Pharm Bull21, 105-108. PubMed  Europe PubMed  I
  110. Tsuda,Y., Wanaka,K., Tada,M., Okamoto,S., Hijikata-Okunomiya,A. and Okada,Y.
    Design of plasma kallikrein inhibitors: functional and structural requirements of plasma kallikrein inhibitors
    Chem Pharm Bull (Tokyo)46, 452-457. PubMed  Europe PubMed  I
  111. Yu,H., Bowden,D.W., Spray,B.J., Rich,S.S. and Freedman,B.I.
    Identification of human plasma kallikrein gene polymorphisms and evaluation of their role in end-stage renal disease
    Hypertension31, 906-911. PubMed  Europe PubMed  M
    112. 1997
  112. [YEAR:15-7-1997]Lin,Y., Harris,R.B., Yan,W., McCrae,K.R., Zhang,H. and Colman,R.W.
    High molecular weight kininogen peptides inhibit the formation of kallikrein on endothelial cell surfaces and subsequent urokinase-dependent plasmin formation
    Blood90, 690-697. PubMed  Europe PubMed
    113. 1996
  113. Katsuura,Y., Okamoto,S., Ohno,N. and Wanaka,K.
    Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats
    Thromb Res82, 361-368. PubMed  Europe PubMed DOI  I
  114. Mashiko,H., Kato,K., Fujii,K. and Takahashi,H.
    Studies on factor XII in porcine plasma: Purification and its conversion to activated form by porcine plasma kallikrein
    Biochim Biophys Acta1296, 198-206. PubMed  Europe PubMed DOI
  115. Yamamoto,T., Shibuya,Y. and Semba,U.
    Species differences in amino acid sequences of Hageman factor and prekallikrein at region around scissile bond in activation
    Immunopharmacology32, 34-38. PubMed  Europe PubMed DOI
    116. 1995
  116. Ohnishi,J., Kihara,T., Hamabata,T., Takahashi,K. and Takahashi,T.
    Cleavage specificity of porcine follipsin
    J Biol Chem270, 19391-19394. PubMed  Europe PubMed DOI
  117. Ulmer,J.S., Lindquist,R.N., Dennis,M.S. and Lazarus,R.A.
    Ecotin is a potent inhibitor of the contact system proteases factor XIIa and plasma kallikrein
    FEBS Lett365, 159-163. PubMed  Europe PubMed DOI
  118. Wachtfogel,Y.T., Hack,C.E., Nuijens,J.H., Kettner,C., Reilly,T.M., Knabb,R.M., Bischoff,R., Tschesche,H., Wenzel,H. and Kucich,U.
    Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation
    Am J Physiol268, H1352-H1357. PubMed  Europe PubMed  I
    119. 1994
  119. Hamabata,T., Okimura,H., Yokoyama,N., Takahashi,T. and Takahashi,K.
    Purification, characterization, and localization of follipsin, a novel serine proteinase from the fluid of porcine ovarian follicles
    J Biol Chem269, 17899-17904. PubMed  Europe PubMed
  120. Page,J.D., DeLa Cadena,R.A., Humphries,J.E. and Colman,R.W.
    An autoantibody to human plasma prekallikrein blocks activation of the contact system
    Br J Haematol87, 81-86. PubMed  Europe PubMed
  121. Pu,X.P., Iwamoto,A., Nishimura,H. and Nagasawa,S.
    Purification and characterization of a novel substrate for plasma kallikrein (PK-120) in human plasma
    Biochim Biophys Acta1208, 338-343. PubMed  Europe PubMed DOI
    122. 1993
  122. [YEAR:30-12-1993]Ciechanowicz,A., Bader,M., Wagner,J. and Ganten,D.
    Extra-hepatic transcription of plasma prekallikrein gene in human and rat tissues
    Biochem Biophys Res Commun197, 1370-1376. PubMed  Europe PubMed DOI
  123. Teno,N., Wanaka,K., Okada,Y., Taguchi,H., Okamoto,U., Hijikata-Okunomiya,A. and Okamoto,S.
    Development of active center-directed plasmin and plasma kallikrein inhibitors and studies on the structure-inhibitory activity relationship
    Chem Pharm Bull (Tokyo)41, 1079-1090. PubMed  Europe PubMed  I
    124. 1992
  124. Imamura,T. and Kambara,T.
    The major plasma kallikrein inhibitor of guinea pig plasma
    Biochim Biophys Acta1118, 261-266. PubMed  Europe PubMed DOI
  125. Okamoto,S., Wanaka,K., Hijikata-Okunomiya,A., Okada,Y. and Katsuura,Y.
    A finding of highly selective synthetic inhibitor of plasma kallikrein; its action to bradykinin generation, intrinsic coagulation and experimental DIC
    Agents Actions Suppl38, 198-205. PubMed  Europe PubMed  I
  126. Tanaka,H., Yamamoto,T., Shibuya,Y., Nishino,N., Tanase,S., Miyauchi,Y. and Kambara,T.
    Activation of human plasma prekallikrein by Pseudomonas aeruginosa elastase. II. Kinetic analysis and identification of scissile bond of prekallikrein in the activation
    Biochim Biophys Acta1138, 243-250. PubMed  Europe PubMed
    127. 1991
  127. Beaubien,G., Rosinski-Chupin,I., Mattei,M.G., Mbikay,M., Chretien,M. and Seidah,N.G.
    Gene structure and chromosomal localization of plasma kallikrein
    Biochemistry30, 1628-1635. PubMed  Europe PubMed
  128. Teno,N., Wanaka,K., Okada,Y., Tsuda,Y., Okamoto,U., Hijikata-Okunomiya,A., Naito,T. and Okamoto,S.
    Development of selective inhibitors against plasma kallikrein
    Chem Pharm Bull (Tokyo)39, 2930-2936. PubMed  Europe PubMed  I
    129. 1990
  129. Seidah,N.G., Sawyer,N., Hamelin,J., Mion,P., Beaubien,G., Brachpapa,L., Rochemont,J., Mbikay,M. and Chretien,M.
    Mouse plasma kallikrein: cDNA structure, enzyme characterization, and comparison of protein and mRNA levels among species
    DNA Cell Biol9, 737-748. PubMed  Europe PubMed
    130. 1989
  130. Hauert,J., Nicoloso,G., Schleuning,W.D., Bachmann,F. and Schapira,M.
    Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis
    Blood73, 994-999. PubMed  Europe PubMed
  131. Seidah,N.G., Ladenheim,R., Mbikay,M., Hamelin,J., Lutfalla,G., Rougeon,F., Lazure,C. and Chretien,M.
    The cDNA structure of rat plasma kallikrein
    DNA8, 563-574. PubMed  Europe PubMed
  132. Tsuda,Y., Teno,N., Okada,Y., Wanaka,K., Bohgaki,M., Hijikata-Okunomiya,A., Okamoto,U., Naito,T. and Okamoto,S.
    Synthesis of tripeptide chloromethyl ketones and examination of their inhibitory effects on plasmin and plasma kallikrein
    Chem Pharm Bull (Tokyo)37, 3108-3111. PubMed  Europe PubMed  I
    133. 1988
  133. Metters,K.M., Rossier,J., Paquin,J., Chretien,M. and Seidah,N.G.
    Selective cleavage of proenkephalin-derived peptides (less than 23,300 daltons) by plasma kallikrein
    J Biol Chem263, 12543-12553. PubMed  Europe PubMed  P
  134. Silverberg,M. and Kaplan,A.P.
    Prekallikrein
    Methods Enzymol163, 85-95. PubMed  Europe PubMed  V
    135. 1987
  135. De La Cadena,R.A., Scott,C.F. and Colman,R.W.
    Evaluation of a microassay for human plasma prekallikrein
    J Lab Clin Med109, 601-607. PubMed  Europe PubMed
  136. Tans,G., Rosing,J., Berrettini,M., Lammle,B. and Griffin,J.H.
    Autoactivation of human plasma prekallikrein
    J Biol Chem262, 11308-11314. PubMed  Europe PubMed
  137. Veloso,D., Silver,L.D., Hahn,S. and Colman,R.W.
    A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface
    Blood70, 1053-1062. PubMed  Europe PubMed
    138. 1986
  138. Bouma,B.N., Kerbiriou,D.M., Baker,J. and Griffin,J.H.
    Characterization of a variant prekallikrein, prekallikrein Long Beach, from a family with mixed cross-reacting material-positive and cross-reacting material-negative prekallikrein deficiency
    J Clin Invest78, 170-176. PubMed  Europe PubMed DOI
  139. Burger,D., Schleuning,W.D. and Schapira,M.
    Human plasma prekallikrein. Immunoaffinity purification and activation to alpha- and beta-kallikrein
    J Biol Chem261, 324-327. PubMed  Europe PubMed
  140. [YEAR:6-5-1986]Chung,D.W., Fujikawa,K., McMullen,B.A. and Davie,E.W.
    Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats
    Biochemistry25, 2410-2417. PubMed  Europe PubMed
  141. Cromlish,J.A., Seidah,N.G. and Chretien,M.
    Selective cleavage of human ACTH, alpha-lipotropin, and the N- terminal glycopeptide at pairs of basic residues by IRCM-serine protease 1
    J Biol Chem261, 10859-10870. PubMed  Europe PubMed
  142. Cromlish,J.A., Seidah,N.G. and Chretien,M.
    A novel serine protease (IRCM-serine protease 1) from porcine neurointermediate and anterior pituitary lobes. Isolation, polypeptide chain structure, inhibitor sensitivity, and substrate specificity with fluorogenic peptide substrates
    J Biol Chem261, 10850-10858. PubMed  Europe PubMed
  143. Schapira,M., Ramus,M.A., Jallat,S., Carvallo,D. and Courtney,M.
    Recombinant alpha1-antitrypsin Pittsburgh (Met 358->Arg) is a potent inhibitor of plasma kallikrein and activated factor XII fragment
    J Clin Invest77, 635-637. PubMed  Europe PubMed DOI  M
  144. Tait,J.F. and Fujikawa,K.
    Identification of the binding site for plasma prekallikrein in human high molecular weight kininogen. A region from residues 185 to 224 of the kininogen light chain retains full binding activity
    J Biol Chem261, 15396-15401. PubMed  Europe PubMed
    145. 1982
  145. Fisher,C.A., Schmaier,A.H., Addonizio,V.P. and Colman,R.W.
    Assay of prekallikrein in human plasma: comparison of amidolytic, esterolytic, coagulation, and immunochemical assays
    Blood59, 963-970. PubMed  Europe PubMed  A
  146. [YEAR:1-2-1982]Gallimore,M.J. and Friberger,P.
    Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein "like" activity in human plasma
    Thromb Res25, 293-298. PubMed  Europe PubMed
    147. 1981
  147. Heimark,R.L. and Davie,E.W.
    Bovine and human plasma prekallikrein
    Methods Enzymol80, 157-172. PubMed  Europe PubMed DOI  V
  148. McRae,B.J., Kurachi,K., Heimark,R.L., Fujikawa,K., Davie,E.W. and Powers,J.C.
    Mapping the active sites of bovine thrombin, factor IXa, factor Xa, factor XIa, factor XIIa, plasma kallikrein, and trypsin with amino acid and peptide thioesters: development of new sensitive substrates
    Biochemistry20, 7196-7206. PubMed  Europe PubMed
  149. Nagase,H. and Barrett,A.J.
    Human plasma kallikrein. A rapid purification method with high yield
    Biochem J193, 187-192. PubMed  Europe PubMed
  150. [YEAR:15-10-1981]Saito,H., Goodnough,L.T., Soria,J., Soria,C., Aznar,J. and Espana,F.
    Heterogeneity of human prekallikrein deficiency (Fletcher trait): evidence that five of 18 cases are positive for cross-reacting material
    N Engl J Med305, 910-914. PubMed  Europe PubMed DOI
    151. 1980
  151. Jackson,C.M. and Nemerson,Y.
    Blood coagulation
    Annu Rev Biochem49, 765-811. PubMed  Europe PubMed DOI
    152. 1979
  152. Davie,E.W., Fujikawa,K., Kurachi,K. and Kisiel,W.
    The role of serine proteases in the blood coagulation cascade
    Adv Enzymol Relat Areas Mol Biol48, 277-318. PubMed  Europe PubMed
  153. Heimark,R.L. and Davie,E.W.
    Isolation and characterization of bovine plasma prekallikrein (Fletcher factor)
    Biochemistry18, 5743-5750. PubMed  Europe PubMed
  154. Saito,H., Goldsmith,G.H., Moroi,M. and Aoki,N.
    Inhibitory spectrum of alpha2-plasmin inhibitor
    Proc Natl Acad Sci U S A76, 2013-2017. PubMed  Europe PubMed
  155. Soulier,J.P. and Gozin,D.
    Assay of Fletcher factor (plasma prekallikrein) using an artificial clotting reagent and a modified chromogenic assay
    Thromb Haemost42, 538-547. PubMed  Europe PubMed  A
  156. Yokosawa,N., Takahashi,N., Inagami,T. and Page,D.L.
    Isolation of completely inactive plasma prorenin and its activation by kallikreins. A possible new link between renin and kallikrein
    Biochim Biophys Acta569, 211-219. PubMed  Europe PubMed
    157. 1978
  157. Gallimore,M.J., Fareid,E. and Stormorken,H.
    The purification of a human plasma kallikrein with weak plasminogen activator activity
    Thromb Res12, 409-420. PubMed  Europe PubMed DOI
    158. 1977
  158. Morita,T., Kato,H., Iwanaga,S., Takada,K., Kimura,T. and Sakakibara,S.
    New fluorogenic substrates for alpha-thrombin, factor Xa, kallikreins, and urokinase
    J Biochem82, 1495-1498. PubMed  Europe PubMed  A
  159. [YEAR:13-10-1977]Tamura,Y., Hirado,M., Okamura,K., Minato,Y. and Fujii,S.
    Synthetic inhibitors of trypsin, plasmin, kallikrein, thrombin, C1r, and C1 esterase
    Biochim Biophys Acta484, 417-422. PubMed  Europe PubMed  I
    160. 1976
  160. Colman,R.W. and Bagdasarian,A.
    Human kallikrein and prekallikrein
    Methods Enzymol45, 303-322. PubMed  Europe PubMed DOI  V
  161. Lahiri,B., Bagdasarian,A., Mitchell,B., Talamo,R.C. and Colman,R.W.
    Antithrombin-heparin cofactor: an inhibitor of plasma kallikrein
    Arch Biochem Biophys175, 737-747. PubMed  Europe PubMed
    162. 1975
  162. Saito,H. and Ratnoff,O.D.
    Alteration of factor VII activity by activated Fletcher factor (a plasma kallikrein): a potential link between the intrinsic and extrinsic blood-clotting systems
    J Lab Clin Med85, 405-415. PubMed  Europe PubMed
    163. 1974
  163. Abildgaard,C.F. and Harrison,J.
    Fletcher factor deficiency: family study and detection
    Blood43, 641-644. PubMed  Europe PubMed  M
  164. Saito,H., Ratnoff,O.D. and Donaldson,V.H.
    Defective activation of clotting, fibrinolytic, and permeability-enhancing systems in human Fletcher trait plasma
    Circ Res34, 641-651. PubMed  Europe PubMed
    165. 1973
  165. Cochrane,C.G., Revak,S.D. and Wuepper,W.G.
    Activation of Hageman factor in solid and fluid phases. A critical role of kallikrein
    J Exp Med138, 1564-1583. PubMed  Europe PubMed
    166. 1970
  166. Hattersley,P.G. and Hayse,D.
    Fletcher factor deficiency: a report of three unrelated cases
    Br J Haematol18, 411-416. PubMed  Europe PubMed  M
    167. 1969
  167. Colman,R.W., Mattler,L. and Sherry,S.
    Studies on the prekallikrein (kallikreinogen)-kallikrein enzyme system of human plasma. 2. Evidence relating the kaolin-activated arginine esterase to plasma kallikrein
    J Clin Invest48, 23-32. PubMed  Europe PubMed DOI  I
  168. [YEAR:29-4-1969]Colman,R.W.
    Activation of plasminogen by human plasma kallikrein
    Biochem Biophys Res Commun35, 273-279. PubMed  Europe PubMed
  169. Ratnoff,O.D., Pensky,J., Ogston,D. and Naff,G.B.
    The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor
    J Exp Med129, 315-331. PubMed  Europe PubMed
    170. 1968
  170. Nagasawa,S., Takahashi,H., Koida,M., Suzuki,T. and Schoenmakers,J.G.
    Partial purification of bovine plasma kallikreinogen, its activation by the Hageman factor
    Biochem Biophys Res Commun32, 644-649. PubMed  Europe PubMed
    171. 1960
  171. Webster,M.E. and Pierce,J.V.
    Studies on plasma kallikrein and its relationship to plasmin
    J Pharmacol Exp Ther130, 484-491. PubMed  Europe PubMed

feedback
Page created 8-September-2023

EMBL-EBI logo

© 2025 EBI
Terms of use